Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells

JUNXIU LIU1*, DAWEI LIU2*, JASMINE J. LIU3, CHANG ZHAO4, SHUZHONG YAO1 and LIANG HONG3

Departments of 1Obstetrics and Gynecology and 2Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China; 3Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612; 4Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA

Received January 17, 2018; Accepted April 17, 2018

DOI: 10.3892/ijo.2018.4437

Abstract. Activity of the voltage-gated Nav1.5 sodium channel has been reported to be involved in cell proliferation, cancer invasion and gene expression. In addition, eicosapentaenoic acid (EPA) has recently been suggested to inhibit ovarian cancer cell growth and suppress tumor metastasis. The present study aimed to explore the association between EPA, the Nav1.5 sodium channel and ovarian cancer cells. Using patch-clamp technique and RNA interference approaches, sodium currents were recorded in epithelial ovarian cancer cells, and it was confirmed that the Nav1.5 channel carried the sodium currents. Furthermore, EPA effectively inhibited sodium currents in a dose-dependent manner, shifted the steady-state inactivation curve of sodium currents to the hyperpolarizing direction and reduced sodium window currents. In addition, EPA induced a shift in the inactivation curve in a dose-dependent manner. Inhibition of the sodium channel, either by EPA or by Nav1.5 knockdown, attenuated ovarian cancer cell migration and proliferation. To the best of our knowledge, the present study is the first to conduct sodium current recording in ovarian cancer cells, and revealed that EPA may inhibit Nav1.5-mediated ovarian cancer cell migration and growth. These findings not only present a potential prognostic biomarker for ovarian cancer, but also provide a strategy towards the development of novel pharmacological treatments for patients with ovarian cancer.

Introduction

Ovarian cancer is one of the most common types of cancer among women worldwide, resulting in >14,000 cases of mortality each year (1). Epithelial ovarian cancer is the most common type of ovarian cancer, which has the highest mortality rate of all gynecological malignancies. This high mortality rate is largely due to the lack of an effective biomarker; in addition, it is difficult to diagnose patients at the early stage of the disease and most patients are diagnosed at advanced stages (2-4).

The Nav1.5 channel protein is a member of the voltage-gated sodium channel family (5). It is the predominant sodium channel in cardiomyocytes and permeates sodium currents to initiate the action potential duration in the heart (6). Previous studies have reported that Nav1.5 channels are expressed in various types of cancer cells, including leukemia (7), prostate cancer (8), breast cancer (9) and colon cancer (10), in which they serve roles in T lymphocyte invasiveness, prostate cell pathological differentiation, breast tumor metastasis and colon cancer transcriptional activity. Furthermore, growing evidence has suggested that the Nav1.5 channel is implicated in ovarian cancer development (11,12), thus suggesting that small molecule-induced inhibition of this channel may lead to a novel pharmacological treatment.

Eicosapentaenoic acid (EPA) is a long-chain n-3 polyunsaturated fatty acid, which has been revealed to reduce blood lipid levels and lessen inflammation. In addition, EPA has been reported to balance metabolism, inhibit proliferation and induce apoptosis (13). EPA may also inhibit human atrial sodium currents in a concentration-dependent manner in cardiomyocytes; these effects may contribute to atrial fibrillation treatment (14). Recently, EPA has been reported to suppress ovarian cancer cell growth, reduce cancer metastasis and kill ovarian cancer cells (15); however, the underlying mechanism by which EPA attenuates ovarian cancer invasion and cell proliferation remains to be elucidated.

The present study demonstrated that EPA may inhibit Nav1.5 sodium currents in the epithelial ovarian cancer cell...
lines TOV112D, A2780 and SKOV3, and that EPA alters the gating process of Nav1.5 and abolishes channel activity in these cells. Furthermore, the effects of EPA on Nav1.5-mediated ovarian cancer cell migration and growth were determined.

Materials and methods

Cell culture. TOV112D, A2780 and SKOV3 ovarian cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). TOV112D cells were cultured in a 1:1 mixture of M199 and MCDB105 media, supplemented with 10% (wt/vol) fetal bovine serum (FBS) (both from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). A2780 and SKOV3 cells were maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% (wt/vol) FBS. In addition, A2780 cells were supplemented with 50 µg/ml insulin (Sigma-Aldrich; Merck KGaA). All cells were maintained at 37°C in an incubator containing 5% (vol/vol) CO₂.

Electrophysiological measurements and analysis. Patch-clamp measurements were performed in whole-cell configuration using an Axopatch 200B amplifier controlled by pClamp10 software through an Axon Digidata 1440A clamp measurements were performed in whole-cell

Cell culture. TOV112D, A2780 and SKOV3 ovarian cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). TOV112D cells were cultured in a 1:1 mixture of M199 and MCDB105 media, supplemented with 10% (wt/vol) fetal bovine serum (FBS) (both from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). A2780 and SKOV3 cells were maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% (wt/vol) FBS. In addition, A2780 cells were supplemented with 50 µg/ml insulin (Sigma-Aldrich; Merck KGaA). All cells were maintained at 37°C in an incubator containing 5% (vol/vol) CO₂.

Electrophysiological measurements and analysis. Patch-clamp measurements were performed in whole-cell configuration using an Axopatch 200B amplifier controlled by pClamp10 software through an Axon Digidata 1440A system (all from Molecular Devices, LLC, Sunnyvale, CA, USA) (16,17). The extracellular solution contained 140 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl₂, 2.5 mM CaCl₂, 10 mM HEPES and 11 mM glucose, adjusted to pH 7.4 with NaOH. The intracellular solution contained 140 mM CsCl, 2 mM MgCl₂, 0.1 mM CaCl₂, 1.1 mM EGTA and 10 mM HEPES, adjusted to pH 7.2 with CsOH. The sodium currents were activated by depolarization to -10 mV for 50 msec from a holding potential of -110 mV. To test steady-state activation, the sodium currents were measured from a holding potential of -110 mV to test potentials ranging between -110 to +70 mV in 10 mV steps, followed by repolarization to -110 mV. To test steady-state inactivation, currents were elicited to 0 mV following repulses ranging between -140 and 0 mV in 10 mV steps for 200 msec. EPA was purchased from Sigma-Aldrich; Merck KGaA and dissolved in ethanol to obtain a stock concentration of 10 mM; butylated-hydroxyanisole was added at a ratio of 0.005% w/v to the stock solution, which was then stored at -80°C (18). EPA was added to the extracellular solution at the desired final concentrations (1-200 µM), and the sodium currents were recorded before and after the addition of EPA, or after EPA washout. All measurements were performed at 22±2°C. Pipettes had 2-4 MΩ access resistance (19,20). Current densities were calculated according to whole-cell current amplitude and capacitance values obtained from the amplifier following electronic subtraction of the capacitive transients.

Dose-responses of channel inhibition were fitted by the Hill equation, as previously described (21): \( \%I = \%_{\text{max}}(B) / (IC_{50} + [B]) \), where \( \%_{\text{max}} \) is the maximal percentage of channel inhibition by blocker \( B \), \( h \) is the Hill coefficient and \( IC_{50} \) is the concentration of an inhibitor required for 50% inhibition. Steady-state activation G-V were fitted by the Boltzmann equation, as described previously (22): \( G/G_{\text{max}} = 1/(1+\exp(V_{1/2} - V)/K) \), where \( G/G_{\text{max}} \) is the relative conductance normalized by the maximal conductance, \( V_{1/2} \) is the potential of half activation, \( V \) is test pulse, and \( k \) is the Boltzmann coefficient. Steady-state inactivation I-V were fitted by the Boltzmann equation: \( II_{\text{max}} = I/(1+\exp(V_{1/2} - V)/K) \).

Western blot analysis. Ovarian cancer cells were rinsed twice with ice-cold PBS, and were then harvested and lysed with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.02% Na₂SO₄, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate and 1% protease inhibitor cocktail; Sigma-Aldrich; Merck KGaA). Protein concentration was quantified using the bicinchoninic acid assay (Beyotime Institute of Biotechnology, Haimen, China) and proteins (25 µg/lane) were separated by 6% SDS-PAGE and transferred to polyvinylidene fluoride membranes (EMD Millipore, Bedford, MA, USA). Membranes were blocked at room temperature for 1 h in 5% non-fat milk dissolved in Tris-buffered saline containing Tween-20 (150 mM NaCl, 50 mM Tris, 0.1% Tween-20; pH 7.5), and were incubated with rabbit anti-human Nav1.5 (1:1,000, ASC-013; Alomone Labs, Jerusalem, Israel) and rabbit anti-GAPDH (1:1,000, #5174; Cell Signaling Technology, Inc., Danvers, MA, USA) primary antibodies at 4°C overnight. Subsequently, membranes were incubated with the goat anti-rabbit horse-radish peroxidase-conjugated secondary antibodies (1:10,000, ab6721; Abcam, Cambridge, UK) for 1.5 h at room temperature. Bands were detected by chemiluminescence assay (Beyotime Institute of Biotechnology) and were semi-quantified using ImageJ version 1.4.3 (National Institutes of Health, Bethesda, MD, USA).

Small interfering (si)RNA transfection. SKOV3 ovarian cancer cells were transfected with siRNA directed against sodium voltage-gated channel α subunit 5 (SCN5A) mRNA (Nav1.5-targeting siRNA; forward, 5'-GAACGGGACACUCUGAUUGTT-3' and reverse, 5'-CACAUCAGAGGCGUGGUUCTT-3') or scramble siRNA-A (forward, 5' CGAACAAUGUGCUUCGUGCCUGTTT-3' and reverse, 5'-CCAGAGCGACAUUGUGCTT-3'), which was used as a control (SiCtl). siRNAs were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Cells (80% confluence) were transfected with 20 or 40 nM siRNA using Lipofectamine® RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. Subsequently, the migration and cell proliferation assays, and the patch clamp technique, were performed 24 h post-transfection.

Nav1.5 transfection. The pRc/CMV plasmid containing the sequence of the human Nav1.5 channel was kindly provided by Dr Alfred L. George Jr (Northwestern University, Chicago, IL, USA). The pRc/CMV-hNav1.5 plasmid contains a 6.1 kb cDNA sequence encoding the human voltage-gated sodium channel Nav1.5 (SCN5A gene product) inserted into the NotI (5') and XbaI (3') sites of the mammalian expression vector, pRc/CMV (5.4 kb). Plasmids containing cDNA encoding human Nav1.5 channels (pRc/CMV-hNav1.5) and green fluorescent protein (GFP; pRc/CMV-GFP) were co-transfected into 293T cells (cat. no. CRL-3216; American Type Culture Collection), which do not possess endogenous Nav1.5 channels. Cells (80% confluence) were transfected with 1 µg/µl plasmids using Lipofectamine® 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The cells were then cultured for 24 h in Dulbecco's modified
Eagle's medium supplemented with 10% FBS (both from Gibco; Thermo Fisher Scientific, Inc.). Patch clamp experiments were conducted 24-48 h after 293T cells were reseeded on coverslips in 6-well plates containing RPMI-1640 medium. A coverslip with 293T cells was placed in a recording chamber containing bath solution on the stage of a fluorescence microscope (Nikon Corporation, Tokyo, Japan), and the transfected cells were identified by the fluorescent signal emitted from GFP (data not shown).

Migration assay. SKOV3 cells were seeded onto 24-well plates (10,000 cells/well). For the wound-healing assay, scratch lesions were created on confluent SKOV3 cells using a 10 µl pipette tip. Wounded cultures were incubated at room temperature for 36 h, and three randomly selected fields at the lesion border were subsequently examined by inverted phase contrast microscopy (IX73; Olympus Corporation, Tokyo, Japan) in order to assess cell migration.

Cell proliferation assay. Cell Counting kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was used to study SKOV3 cell proliferation, according to the manufacturer's protocol. SKOV3 cells were seeded at a density of 5x10³ cells/well in 96-well plates, after which 10 µl CCK-8 solution was added to each well. Absorbance was measured at 450 nm using a multplate reader (Lambda Bio-20; Beckman Coulter, Inc., Brea, CA, USA). Cell viability was expressed as a percentage of that of the control (untreated) cells.

Data analysis. All data are presented as the means ± standard error of the mean. The n value denotes the number of independent experiments conducted, unless otherwise stated. Significance between means was determined using either the two-tailed Student's paired t-test or one-way analysis of variance with Dunnett's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.

Results

Characterization of voltage-gated sodium channel Nav1.5 currents in ovarian cancer cells. The voltage-gated sodium channel Nav1.5 has been implicated in ovarian cancer (12), the present study detected Nav1.5 expression in the ovarian cancer cell lines TOV112D, A2780 and SKOV3. The results of a western blot analysis indicated that Nav1.5 channel protein was expressed in the three ovarian cancer cells (Fig. 1A and B). Although the voltage-gated sodium channels have been associated with ovarian cancer development, to the best of our knowledge, the functional sodium currents have not been examined in ovarian cancer cells (11,12). Using whole cell patch-clamp configuration, the present study observed fast inactivation currents in ovarian cancer cells (Fig. 1C). The currents elicited by depolarization to -10 mV were further measured prior to and after the addition of 10 µM TTX (Fig. 1D). TTX had IC₅₀ values of 5.8, 9.2 and 3.1 µM in

Figure 1. Characterization of voltage-gated sodium currents in ovarian cancer cells. (A and B) Western blot analysis of Nav1.5 protein expression in the ovarian cancer cell lines SKOV3, A2780 and TOV112D (n=7). (C) Voltage-gated sodium currents recorded in SKOV3, A2780 and TOV112D cells. Currents were activated by depolarization to -10 mV for 50 msec from a holding potential of -110 mV. (D) Sodium currents recorded in ovarian cancer cells prior to and following the addition of 10 µM TTX. (E) Dose-dependent effects of TTX on sodium current inhibition (n=5 for each concentration; data are presented as the means ± standard error of the mean), curves are Hill fits of the data points. TTX, tetrodotoxin.
SKOV3, A2780, and TOV112D ovarian cancer cells, respectively (Fig. 1E and Table I). Since the IC\textsubscript{50} values were in the micromolar range, it was suggested that these cell lines were of the TTX-resistant subtype (23).

Effects of Nav1.5 knockdown on sodium currents. To further analyze sodium currents in ovarian cancer cells, the RNA interference approach was used to knockdown Nav1.5 expression in SKOV3 cancer cells. Transfection with Nav1.5 siRNA resulted in a significant reduction in the protein expression levels of Nav1.5, whereas SiCtl did not alter Nav1.5 expression (Fig. 2A and B). The reduction in Nav1.5 protein expression was associated with >90% reduction of the maximal currents recorded when the cells were depolarized to -10 mV (Fig. 2C and D). These results indicated that the sodium currents were predominantly carried by the Nav1.5 channel, and that Nav1.5 channels are functionally expressed in ovarian cancer cells.

EPA functionally inhibits Nav1.5 sodium currents in ovarian cancer cells. After examining Nav1.5 channel currents in ovarian cancer cells, the present study aimed to determine whether EPA exerted effects on them (Fig. 3). EPA was previously reported to block the Nav1.5 channel in cardiomyocytes (14), and to inhibit ovarian cancer cell growth and reduce cancer metastasis (15). The present study hypothesized that EPA may affect the Nav1.5 channel in ovarian cancer cells; the results indicated that treatment with 15 µM EPA blocked ~60% sodium currents in SKOV3 cancer cells (Fig. 3A, B and E), and this inhibition could be completely reversed following EPA washout (Fig. 3C and D). Furthermore, 15 µM EPA blocked sodium currents to similar extents in A2780 and TOV112D cancer cells (Fig. 3F and G). Various concentrations of EPA were then used to generate a dose-response curve; the IC\textsubscript{50} values for EPA in SKOV3, A2780 and TOV112D cells were 11.8, 19.6 and 18.1 µM, respectively (Fig. 3H and Table I). These results indicated that EPA may effectively block Nav1.5 sodium currents in ovarian cancer cells.

EPA shifts the steady-state inactivation curve of sodium currents in a hyperpolarizing direction. Previous studies demonstrated that EPA induces Nav1.5 channels to enter an inactive state and stabilizes the channel, thus resulting in a reduction of sodium currents (24,25). The present study investigated the effects of EPA on SKOV3 cancer cells (Fig. 4); the results indicated that 15 µM EPA shifted the steady-state inactivation of sodium currents by ~20 mV to the hyperpolarizing direction (Fig. 4A and C and Table II), whereas it had almost no effect on channel activation (Fig. 4B and C and Table III). The window currents were obtained by plotting the area where steady-state inactivation and activation overlap; EPA significantly reduced the Nav1.5 sodium window currents (Fig. 4D). In addition, the shifts of inactivation induced by EPA, along with the rise of EPA concentration, were gradually enhanced to the hyperpolarizing direction, indicating that the shift of steady-state inactivation is EPA dose-dependent (Fig. 5 and Table II). In the other two ovarian cancer cells (A2780 and TOV112D cells), 15 µM EPA also altered steady-state inactivation curves to the hyperpolarizing direction, and did not significantly alter steady-state activation curves (Fig. 6 and Tables II and III). Subsequently, the present study transfected 293T cells with Nav1.5 cDNA; the results revealed that EPA hyperpolarized the slow inactivation curve of Nav1.5 channels and reduced Nav1.5 channel availability, which are consistent with the results in ovarian cancer cells (Fig. 7). In conclusion, these data suggested that EPA may enhance sodium channel...
inactivation and stabilize the inactivation gate of the channel, thus indicating that EPA-induced reductions in sodium currents may be due to more channels remaining in the inactivated state post-activation.

Inhibition of the Nav1.5 channel attenuates SKOV3 cell migration. The present study also aimed to examine the function of Nav1.5 during the process of ovarian cancer development. The Nav1.5 channel has been reported to promote cancer cell invasion (26); therefore, inhibition of this channel was expected to reduce cell migration. The present study used a wound-healing assay to investigate the effects of either Nav1.5 knockdown or Nav1.5 functional inhibition by EPA on SKOV3 ovarian cancer cell migration. The cells were divided into five groups: Group 1, control; group 2, cells transfected with

Table I. IC50 values, as fitted by the Hill equation, of TTX- or EPA-induced channel inhibition in ovarian cancer cells. Sodium currents were recorded in independent cultures.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Cell type</th>
<th>IC50 (µM)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTX</td>
<td>SKOV3</td>
<td>5.8±0.4</td>
<td>5</td>
</tr>
<tr>
<td>TTX</td>
<td>A2780</td>
<td>9.2±0.7</td>
<td>5</td>
</tr>
<tr>
<td>TTX</td>
<td>TOV112D</td>
<td>3.1±0.3</td>
<td>5</td>
</tr>
<tr>
<td>EPA</td>
<td>SKOV3</td>
<td>11.8±1.0</td>
<td>6</td>
</tr>
<tr>
<td>EPA</td>
<td>A2780</td>
<td>19.6±1.8</td>
<td>6</td>
</tr>
<tr>
<td>EPA</td>
<td>TOV112D</td>
<td>18.1±1.2</td>
<td>6</td>
</tr>
</tbody>
</table>

EPA, eicosapentaenoic acid; IC50, half maximal inhibitory concentration; TTX, tetrodotoxin.

Table II. $V_{1/2}$ of voltage dependence of steady-state inactivation of sodium channels prior to and after treatment with EPA. Sodium currents were recorded in independent cultures.

<table>
<thead>
<tr>
<th>Group</th>
<th>Cell line</th>
<th>$V_{1/2}$ (mV)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>SKOV3</td>
<td>-67.3±8.4</td>
<td>7</td>
</tr>
<tr>
<td>Control</td>
<td>A2780</td>
<td>-78.0±3.4</td>
<td>8</td>
</tr>
<tr>
<td>Control</td>
<td>TOV112D</td>
<td>-70.6±3.4</td>
<td>6</td>
</tr>
<tr>
<td>EPA 15 µM</td>
<td>SKOV3</td>
<td>-99.0±5.8</td>
<td>7</td>
</tr>
<tr>
<td>EPA 15 µM</td>
<td>A2780</td>
<td>-91.1±3.2</td>
<td>8</td>
</tr>
<tr>
<td>EPA 15 µM</td>
<td>TOV112D</td>
<td>-85.8±4.1</td>
<td>6</td>
</tr>
<tr>
<td>EPA 1 µM</td>
<td>SKOV3</td>
<td>-78.1±3.7</td>
<td>10</td>
</tr>
<tr>
<td>EPA 5 µM</td>
<td>SKOV3</td>
<td>-87.4±3.5</td>
<td>9</td>
</tr>
<tr>
<td>EPA 50 µM</td>
<td>SKOV3</td>
<td>-101.4±7.5</td>
<td>9</td>
</tr>
<tr>
<td>EPA 200 µM</td>
<td>SKOV3</td>
<td>-106.9±4.5</td>
<td>10</td>
</tr>
</tbody>
</table>

Table III. $V_{1/2}$ values from Boltzmann fits of voltage dependence of activation of sodium channels prior to and after treatment with EPA. Sodium currents were recorded in independent cultures.

<table>
<thead>
<tr>
<th>Group</th>
<th>Cell line</th>
<th>$V_{1/2}$ (mV)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>SKOV3</td>
<td>-31.1±3.4</td>
<td>7</td>
</tr>
<tr>
<td>Control</td>
<td>A2780</td>
<td>-38.0±3.3</td>
<td>8</td>
</tr>
<tr>
<td>Control</td>
<td>TOV112D</td>
<td>-26.5±4.3</td>
<td>6</td>
</tr>
<tr>
<td>EPA 15 µM</td>
<td>SKOV3</td>
<td>-32.6±3.3</td>
<td>7</td>
</tr>
<tr>
<td>EPA 15 µM</td>
<td>A2780</td>
<td>-34.9±4.0</td>
<td>8</td>
</tr>
<tr>
<td>EPA 15 µM</td>
<td>TOV112D</td>
<td>-29.8±4.4</td>
<td>6</td>
</tr>
</tbody>
</table>

Figure 3. Inhibition of sodium currents by EPA. Voltage-gated sodium currents recorded in SKOV3 ovarian cancer cells (A) prior to and (B) following the addition of 15 µM EPA into the bath solution. Currents were measured from a holding potential of -110 mV to test potentials ranging from -110 to +70 mV in 10 mV steps, followed by repolarization to -110 mV. (C) Time courses of inhibition produced by 15 µM EPA. Sodium currents were evoked every 10 sec with 50 msec duration pulses to -10 mV from a holding potential of -110 mV. (D) Bars indicate stable currents shown in (C) (n=6). *P<0.05 vs. the control. Representative normalized peak I-V plot of currents recorded from (E) SKOV3, (F) A2780 and (G) TOV112D ovarian cancer cells prior to and after treatment with 15 µM EPA (n=6 for each cell line; data are presented as the means ± standard error of the mean). (H) Dose-dependent effects of EPA on sodium current inhibition (n=6 for each concentration; data are presented as the means ± standard error of the mean), curves are Hill fits of the data points. EPA, eicosapentaenoic acid.
Nav1.5 siRNA; group 3, cells transfected with SiCtl; group 4, cells treated with 200 µM EPA; group 5, cells transfected with Nav1.5 siRNA and treated with 200 µM EPA (Fig. 8). The results demonstrated that EPA was able to inhibit SKOV3 cell migration in a dose-dependent manner (Fig. 8C), and migration was significantly reduced in Nav1.5 siRNA-transfected cells compared with in SiCtl cells (Fig. 8A and B). Notably, the migration of Nav1.5 siRNA-transfected cells was not further reduced by 200 µM EPA, thus indicating that the impaired invasion of these cells was due to the absence of Nav1.5 activities (Fig. 8B). These results suggested that the Nav1.5 channel may have a critical role in ovarian cancer migration, and the effects of EPA on cell migration were due to the blockade of Nav1.5 sodium channels.

EPA inhibits SKOV3 cell proliferation via Nav1.5. Using the CCK-8 assay, it was revealed that EPA inhibited the proliferation of SKOV3 cells in a dose-dependent manner (Fig. 9A).
Figure 6. Effects of EPA on the steady-state inactivation of sodium currents in A2780 and TOV112D ovarian cancer cells. (A) Steady-state inactivation curve and (B) activation curve of sodium currents prior to and after treatment with 15 µM EPA in A2780 cells. (C) Steady-state activation and inactivation $V_{1/2}$ prior to and after treatment with 15 µM EPA in A2780 cells (n=8). *P<0.05 vs. the control. (D) Steady-state inactivation curve and (E) activation curve of sodium currents prior to and after treatment with 15 µM EPA in TOV112D cells. (F) Steady-state activation and inactivation $V_{1/2}$ prior to and after treatment with 15 µM EPA in TOV112D cells (n=6). *P<0.05 vs. the control. EPA, eicosapentaenoic acid.

Figure 7. Effects of EPA on steady-state inactivation and activation of the Nav1.5 currents in 293T cells. (A) Steady-state inactivation curve of Nav1.5 currents prior to and after treatment with 5 µM EPA. Currents were elicited to 0 mV following prepulses ranging between -140 and 0 mV in 10 mV steps for 200 msec (n=6; data are presented as the means ± standard error of the mean). (B) Steady-state activation curve of the Nav1.5 sodium channel prior to and after treatment with 5 µM EPA. Currents were measured from a holding potential of -110 mV to test potentials ranging between -110 and +70 mV in 10 mV steps (n=6; data are presented as the means ± standard error of the mean). (A and B) Curves are Boltzmann fits of the data points. (C) Steady-state activation and inactivation $V_{1/2}$ prior to and after treatment with 5 µM EPA (n=6; data are presented as the means ± standard error of the mean). *P<0.05 vs. the control. (D) Normalized I-V plot of Nav1.5 currents recorded from cells prior to and after treatment with 5 µM EPA (n=6; data are presented as the means ± standard error of the mean). EPA, eicosapentaenoic acid.
Knockdown of Nav1.5 in SKOV3 cells resulted in a marked decrease in the inhibitory effect of 15 µM EPA on SKOV3 cell proliferation. In addition, 15 µM EPA alone still inhibited SKOV3 cell proliferation in SiCtl-transfected cells (Fig. 9B). Collectively, these data indicated that inhibition of Nav1.5 by EPA may reduce ovarian cell proliferation.

**Discussion**

To the best of our knowledge, the present study is the first to record voltage-gated sodium currents in ovarian cancer cells; the currents were further characterized to be carried by the Nav1.5 channel. In addition, EPA effectively inhibited sodium...
currents in the ovarian cancer cells, and shifted the steady-state inactivation of voltage-gated sodium currents to the hyperpolarizing direction, thus resulting in reduced window currents and blockade of the channel. The functional inhibition of Nav1.5 sodium channels by EPA attenuated ovarian cancer cell migration and proliferation.

EPA is a member of the family of long-chain n-3 polyunsaturated fatty acids. It is usually used as a nutritional supplement to treat cancer-associated cachexia (27). Previous studies reported that EPA exerts a direct effect on cancer development, and induces cancer apoptosis, suppresses cell migration and affects cancer metastasis (15,28,29). EPA has been hypothesized to regulate the apoptotic signaling pathway, inhibit tumor migration and enhance the effects of anticancer drugs. EPA was previously reported to block endogenous Nav1.5 channels in cardiomyocytes; EPA was able to induce Nav1.5 channels to enter an inactive state, thus resulting in a reduction of sodium currents (14,18). In addition, another study identified position N406 of the Nav1.5 channel as the key interacting site with EPA, and an N406 mutation (N406K) significantly decreases the inhibitory effects of EPA on Nav1.5 sodium currents (24). The present study revealed that EPA reduced Nav1.5-mediated ovarian cancer cell migration and growth, and observed that EPA blocked sodium currents in ovarian cancer cells in a dose-dependent manner. EPA IC_{50} values were measured and it was revealed that EPA was able to inhibit sodium currents in various ovarian cancer cells within similar concentration ranges; this is consistent with previous findings regarding the effects of EPA on Nav1.5 channels in cardiomyocytes (14). Furthermore, this study indicated that EPA shifted the steady-state inactivation curve of sodium currents to a hyperpolarizing direction; however, it had almost no effect on the steady-state activation curve, thus resulting in a decrease of Nav1.5 channel window currents.

The window currents are defined as the currents that flux through voltage-gated sodium channels in a narrow voltage range, in which steady-state inactivation and activation states overlap (30). At transmembrane potentials beyond this window, channels cannot generate any sodium currents due to the channels being either in a closed state or an inactivated state. Therefore, the window current serves an important role in the function of voltage-gated sodium channels (31). The sodium channel window currents usually control action potential shape in excitable cells, such as cardiomyocytes and neurons; however, upregulated window currents have been reported to trigger arrhythmias or dysfunctional excitation-contraction coupling (32,33). The present study demonstrated that EPA effectively inhibited window currents carried by the Nav1.5 channel in ovarian cancer cells, and reduced cancer cell migration and proliferation.

It has been reported that a neonatal splice variant of the Nav1.5 channel (nNav1.5) is predominantly expressed in the highly metastatic MDA-MB-231 breast cancer cell line; therefore, nNav1.5 has been proposed as a marker with clinical potential for the management of metastatic breast cancer (34). Compared with the adult variant Nav1.5 (aNav1.5), nNav1.5 exhibits a 6-amino acid substitution in the S3 and S4 loop in domain I, and one amino acid substitution in S4 of domain I (35). This structural difference produces unique properties for nNav1.5. For example, in nNav1.5 voltage-dependence of activation is shifted in the depolarized direction, and is much slower to open and close. The V_{1/2} of activation for nNav1.5 is -19 mV, whereas for aNav1.5 it is -28 mV (35). The present results indicated that the V_{1/2} of activation for Nav1.5 was between -26 and -38 mV in ovarian cancer cells, thus suggesting that being different from breast cancer cells, aNav1.5 may be the predominant Nav1.5 in ovarian cancer cells.

It is well known that ion channels have important roles in the growth and migration of cancer cells (36-41), and cell proliferation and invasion are crucial hallmarks for cancer development (42). In addition, the association between cancer proliferation and resting potential has been supported by studies in breast cancer cells, hepatocellular carcinoma cells, fibrosarcoma cells and ovarian cancer cells (43). It was revealed that cancer cells have low resting potential and tend to be more depolarized than normal cells. The resting potential of ovarian tumor cells was approximately -10 mV, in which most Nav1.5 channels are activated (44). The low resting potential may activate voltage-dependent Nav1.5 channels in ovarian cancer cells and provide an explanation for the mechanism underlying Nav1.5-dependent proliferation of cancer cells. There are several theories regarding how sodium currents contribute to cancer cell growth and tumor invasiveness. One explanation is that sodium ions permeate from the sodium channel, thus leading to the entry of calcium through the sodium-calcium exchanger (NCX), which induces Ca^{2+}-dependent signaling to promote cancer cell invasion and metastatic progression (26). Another theory proposed is that the local sodium concentration is able to activate the Na^+/H^+ exchanger (NHE) and enhance H^+ efflux, consequently leading to increased intracellular alkalinisation and decreased extracellular pH. Increased glycolytic metabolism in cancer cells gives rise to an excessive production of intracellular acidity; therefore, intracellular alkalinisation potentially facilitates cancer metabolism. In addition, a lower extracellular pH environment activates pH-dependent cathepsin proteases and invadopodia formation, which in turn, may enhance cancer cell invasion (45). In the present study, the sodium currents that promote ovarian cancer cell migration and proliferation were suppressed by EPA treatment or by Nav1.5-targeting siRNA, thus indicating that Nav1.5-mediated sodium currents have crucial roles during the development of ovarian cancer. However, whether Nav1.5 induced Ca^{2+}-dependent signaling by stimulating NCX activity to accelerate ovarian tumor progression, or activated NHE to increase H^+ efflux, in order to provide a favorable environment for ovarian cancer growth, remain unclear; further studies are required to address these uncertainties.

In conclusion, to the best of our knowledge, the present study was the first to record Nav1.5-mediated sodium currents in ovarian cancer cells; the results revealed that Nav1.5 currents were effectively inhibited by EPA. The mechanism by which EPA blocked the Nav1.5 channel was due to increased inactivation of the Nav1.5 sodium channel, thus resulting in a reduction in window currents and blockade of the channel. These findings highlight the importance of Nav1.5 in cancer development, and may provide novel insights into the development of chemotherapeutics for ovarian cancer.
Acknowledgements

The authors would like to thank Dr A.L. George Jr (Northwestern University, Chicago, IL, USA) for the hNav1.5 channel cDNA, Dr D. Zhang (Sun Yat-Sen University, Guangzhou, Guangdong, China) for helpful discussions, and Dr G. Yao (Sun Yat-Sen University, Guangzhou, Guangdong, China) and other members of the laboratory for insightful comments on the manuscript.

Funding

The present study was supported by the Young Scientists Fund of the National Natural Science Foundation of China (grant no. 81502226) and the Guangdong Natural Science Foundation (grant no. 2014A030313038).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

SY and LH designed the project; JL, DL, JYL and CZ performed research; JL, DL, SY and LH analyzed the data; JL and LH wrote the paper. All authors read and edited the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References